# Efficacy of bladder instillations with adelmidrol and sodium hyaluronate for the treatment of symptomatic radiation cystitis

**Authors:** Francesco M. Bracco, Enrico Ammirati, Alessandro Giammò, Paolo Gontero

PMC · DOI: 10.3389/fsurg.2025.1735532 · Frontiers in Surgery · 2026-01-27

## TL;DR

This study shows that bladder instillations with Adelmidrol and sodium hyaluronate significantly reduce symptoms of radiation cystitis, such as pain and hematuria.

## Contribution

The study demonstrates the efficacy of a specific combination of Adelmidrol and sodium hyaluronate for treating radiation cystitis symptoms.

## Key findings

- Pelvic pain decreased significantly in 66.7% of patients after treatment.
- Gross hematuria and urgency were reduced in the majority of patients.
- Incontinence showed some improvement but was not statistically significant.

## Abstract

Radiation cystitis (RC) is a well–recognized complication of pelvic irradiation, manifesting as symptoms and signs such as hematuria, pain during urination, chronic pelvic pain, urgency and incontinence, which negatively impact patients' quality of life. We conducted a retrospective observational clinical investigation to evaluate the effect of bladder instillation with Adelmidrol (ADM) and sodium hyaluronate (HA) in patients with symptomatic RC.

We collected data from the patients' clinical records for all patients treated in our hospital with a diagnosis of RC and undergoing a cycle of 8 weekly 60 min bladder instillations with 50 mL a solution of 2% ADM + 0.1% HA. We evaluated the presence of pain (measured with the VAS score), urinary urgency/frequency, macroscopic hematuria and incontinence (all registered as a dichotomous variable present/absent) before and at the end of the treatment.

Pelvic pain, evaluated by Visual Analogue Scale (VAS), improved in 66.7% of patients, significantly decreasing from a mean score of 3.8 ± 0.47–1.1 ± 0.3 (p < 0.0001). Gross hematuria and urgency, presented by 83.3% and 90.0% of patients, were reported by 6.7% and 33.3%, respectively, after the end of treatment (p < 0.0001). Incontinence, at first reported by 43.3% of the considered patients, disappeared in 16.7% of the subjects (n.s.).

These results suggest the beneficial effect of ADM + HA intravesical instillations in managing RC symptoms, especially pain, gross hematuria and urgency.

## Linked entities

- **Chemicals:** Adelmidrol (PubChem CID 176874)
- **Diseases:** radiation cystitis (MONDO:0004112)

## Full-text entities

- **Diseases:** Incontinence (MESH:D014549), hematuria (MESH:D006417), chronic pelvic pain (MESH:D011472), pain (MESH:D010146), RC (MESH:D011832), Pelvic pain (MESH:D017699)
- **Chemicals:** HA (MESH:D006820), ADM (MESH:C552602)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12888785/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12888785/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12888785/full.md

---
Source: https://tomesphere.com/paper/PMC12888785